4	B:C0034407
-	I:C0034407
Anilino	I:C0034407
-	I:C0034407
2	I:C0034407
-	I:C0034407
pyridylquinazolines	I:C0034407
and	O
-	O
pyrimidines	O
as	O
Highly	O
Potent	O
and	O
Nontoxic	O
Inhibitors	O
of	O
Breast	O
Cancer	I:C0761993
Resistance	I:C0761993
Protein	I:C0761993
(	O
ABCG2	O
)	O
.	O

4	O
-	I:C0034407
Anilino	I:C0034407
-	I:C0034407
2	I:C0034407
-	I:C0034407
pyridylquinazolines	I:C0034407
and	O
-	O
pyrimidines	B:C0034289
as	O
Highly	O
Potent	O
and	O
Nontoxic	O
Inhibitors	O
of	O
Breast	O
Cancer	I:C0761993
Resistance	I:C0761993
Protein	I:C0761993
(	O
ABCG2	O
)	O
.	O

4	O
-	I:C0034407
Anilino	I:C0034407
-	I:C0034407
2	I:C0034407
-	I:C0034407
pyridylquinazolines	I:C0034407
and	O
-	O
pyrimidines	O
as	O
Highly	O
Potent	O
and	O
Nontoxic	O
Inhibitors	B:C0243077
of	O
Breast	O
Cancer	I:C0761993
Resistance	I:C0761993
Protein	I:C0761993
(	O
ABCG2	O
)	O
.	O

4	O
-	I:C0034407
Anilino	I:C0034407
-	I:C0034407
2	I:C0034407
-	I:C0034407
pyridylquinazolines	I:C0034407
and	O
-	O
pyrimidines	O
as	O
Highly	O
Potent	O
and	O
Nontoxic	O
Inhibitors	O
of	O
Breast	B:C0761993
Cancer	I:C0761993
Resistance	I:C0761993
Protein	I:C0761993
(	O
ABCG2	O
)	O
.	O

4	O
-	I:C0034407
Anilino	I:C0034407
-	I:C0034407
2	I:C0034407
-	I:C0034407
pyridylquinazolines	I:C0034407
and	O
-	O
pyrimidines	O
as	O
Highly	O
Potent	O
and	O
Nontoxic	O
Inhibitors	O
of	O
Breast	O
Cancer	I:C0761993
Resistance	I:C0761993
Protein	I:C0761993
(	O
ABCG2	B:C0761993
)	O
.	O

Multidrug	O
resistance	O
(	O
MDR	O
)	O
mediated	O
by	O
ATP	B:C0242738
-	I:C0242738
binding	I:C0242738
cassette	I:C0242738
(	I:C0242738
ABC	I:C0242738
)	I:C0242738
transport	I:C0242738
proteins	I:C0242738
remains	O
a	O
major	O
problem	O
in	O
the	O
chemotherapeutic	O
treatment	I:C3665472
of	O
cancer	O
and	O
might	O
be	O
overcome	O
by	O
inhibition	O
of	O
the	O
transporter	O
.	O

Multidrug	O
resistance	O
(	O
MDR	O
)	O
mediated	O
by	O
ATP	O
-	I:C0242738
binding	I:C0242738
cassette	I:C0242738
(	I:C0242738
ABC	I:C0242738
)	I:C0242738
transport	I:C0242738
proteins	I:C0242738
remains	O
a	O
major	O
problem	O
in	O
the	O
chemotherapeutic	B:C3665472
treatment	I:C3665472
of	O
cancer	O
and	O
might	O
be	O
overcome	O
by	O
inhibition	O
of	O
the	O
transporter	O
.	O

Multidrug	O
resistance	O
(	O
MDR	O
)	O
mediated	O
by	O
ATP	O
-	I:C0242738
binding	I:C0242738
cassette	I:C0242738
(	I:C0242738
ABC	I:C0242738
)	I:C0242738
transport	I:C0242738
proteins	I:C0242738
remains	O
a	O
major	O
problem	O
in	O
the	O
chemotherapeutic	O
treatment	I:C3665472
of	O
cancer	B:C0027651
and	O
might	O
be	O
overcome	O
by	O
inhibition	O
of	O
the	O
transporter	O
.	O

Multidrug	O
resistance	O
(	O
MDR	O
)	O
mediated	O
by	O
ATP	O
-	I:C0242738
binding	I:C0242738
cassette	I:C0242738
(	I:C0242738
ABC	I:C0242738
)	I:C0242738
transport	I:C0242738
proteins	I:C0242738
remains	O
a	O
major	O
problem	O
in	O
the	O
chemotherapeutic	O
treatment	I:C3665472
of	O
cancer	O
and	O
might	O
be	O
overcome	O
by	O
inhibition	O
of	O
the	O
transporter	B:C0596902
.	O

Because	O
of	O
the	O
lack	O
of	O
understanding	O
,	O
the	O
complex	O
mechanisms	O
involved	O
in	O
the	O
transport	B:C1519628
process	I:C1519628
,	O
in	O
particular	O
for	O
breast	O
cancer	I:C0761993
resistance	I:C0761993
protein	I:C0761993
(	O
BCRP	O
/	O
ABCG2	O
)	O
,	O
there	O
is	O
a	O
persistent	O
need	O
for	O
studies	O
of	O
inhibitors	O
of	O
ABCG2	O
.	O

Because	O
of	O
the	O
lack	O
of	O
understanding	O
,	O
the	O
complex	O
mechanisms	O
involved	O
in	O
the	O
transport	O
process	I:C1519628
,	O
in	O
particular	O
for	O
breast	B:C0761993
cancer	I:C0761993
resistance	I:C0761993
protein	I:C0761993
(	O
BCRP	O
/	O
ABCG2	O
)	O
,	O
there	O
is	O
a	O
persistent	O
need	O
for	O
studies	O
of	O
inhibitors	O
of	O
ABCG2	O
.	O

Because	O
of	O
the	O
lack	O
of	O
understanding	O
,	O
the	O
complex	O
mechanisms	O
involved	O
in	O
the	O
transport	O
process	I:C1519628
,	O
in	O
particular	O
for	O
breast	O
cancer	I:C0761993
resistance	I:C0761993
protein	I:C0761993
(	O
BCRP	B:C0761993
/	O
ABCG2	O
)	O
,	O
there	O
is	O
a	O
persistent	O
need	O
for	O
studies	O
of	O
inhibitors	O
of	O
ABCG2	O
.	O

Because	O
of	O
the	O
lack	O
of	O
understanding	O
,	O
the	O
complex	O
mechanisms	O
involved	O
in	O
the	O
transport	O
process	I:C1519628
,	O
in	O
particular	O
for	O
breast	O
cancer	I:C0761993
resistance	I:C0761993
protein	I:C0761993
(	O
BCRP	O
/	O
ABCG2	B:C0761993
)	O
,	O
there	O
is	O
a	O
persistent	O
need	O
for	O
studies	O
of	O
inhibitors	O
of	O
ABCG2	O
.	O

Because	O
of	O
the	O
lack	O
of	O
understanding	O
,	O
the	O
complex	O
mechanisms	O
involved	O
in	O
the	O
transport	O
process	I:C1519628
,	O
in	O
particular	O
for	O
breast	O
cancer	I:C0761993
resistance	I:C0761993
protein	I:C0761993
(	O
BCRP	O
/	O
ABCG2	O
)	O
,	O
there	O
is	O
a	O
persistent	O
need	O
for	O
studies	O
of	O
inhibitors	B:C0243077
of	O
ABCG2	O
.	O

Because	O
of	O
the	O
lack	O
of	O
understanding	O
,	O
the	O
complex	O
mechanisms	O
involved	O
in	O
the	O
transport	O
process	I:C1519628
,	O
in	O
particular	O
for	O
breast	O
cancer	I:C0761993
resistance	I:C0761993
protein	I:C0761993
(	O
BCRP	O
/	O
ABCG2	O
)	O
,	O
there	O
is	O
a	O
persistent	O
need	O
for	O
studies	O
of	O
inhibitors	O
of	O
ABCG2	B:C0761993
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
a	O
systematic	O
series	O
of	O
4	B:C0034407
-	I:C0034407
substituted	I:C0034407
-	I:C0034407
2	I:C0034407
-	I:C0034407
pyridylquinazolines	I:C0034407
in	O
terms	O
of	O
their	O
inhibitory	O
potency	O
as	O
well	O
as	O
selectivity	O
toward	O
ABCG2	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
a	O
systematic	O
series	O
of	O
4	O
-	I:C0034407
substituted	I:C0034407
-	I:C0034407
2	I:C0034407
-	I:C0034407
pyridylquinazolines	I:C0034407
in	O
terms	O
of	O
their	O
inhibitory	O
potency	O
as	O
well	O
as	O
selectivity	O
toward	O
ABCG2	B:C0761993
.	O

For	O
comparison	O
,	O
the	O
quinazoline	B:C0034407
scaffold	I:C0034407
was	O
reduced	O
to	O
the	O
significantly	O
smaller	O
4	O
-	I:C0034289
methylpyrimidine	I:C0034289
basic	O
structure	O
.	O

For	O
comparison	O
,	O
the	O
quinazoline	O
scaffold	I:C0034407
was	O
reduced	O
to	O
the	O
significantly	O
smaller	O
4	B:C0034289
-	I:C0034289
methylpyrimidine	I:C0034289
basic	O
structure	O
.	O

Furthermore	O
,	O
the	O
cytotoxicity	B:C0596402
and	O
the	O
ability	O
to	O
reverse	O
MDR	O
was	O
tested	O
with	O
the	O
chemotherapeutic	O
agents	I:C0729502
SN	O
-	I:C0142710
38	I:C0142710
and	O
mitoxantrone	O
(	O
mitoxantrone	O
)	O
.	O

Furthermore	O
,	O
the	O
cytotoxicity	O
and	O
the	O
ability	O
to	O
reverse	O
MDR	O
was	O
tested	O
with	O
the	O
chemotherapeutic	B:C0729502
agents	I:C0729502
SN	O
-	I:C0142710
38	I:C0142710
and	O
mitoxantrone	O
(	O
mitoxantrone	O
)	O
.	O

Furthermore	O
,	O
the	O
cytotoxicity	O
and	O
the	O
ability	O
to	O
reverse	O
MDR	O
was	O
tested	O
with	O
the	O
chemotherapeutic	O
agents	I:C0729502
SN	B:C0142710
-	I:C0142710
38	I:C0142710
and	O
mitoxantrone	O
(	O
mitoxantrone	O
)	O
.	O

Furthermore	O
,	O
the	O
cytotoxicity	O
and	O
the	O
ability	O
to	O
reverse	O
MDR	O
was	O
tested	O
with	O
the	O
chemotherapeutic	O
agents	I:C0729502
SN	O
-	I:C0142710
38	I:C0142710
and	O
mitoxantrone	B:C0026259
(	O
mitoxantrone	O
)	O
.	O

Furthermore	O
,	O
the	O
cytotoxicity	O
and	O
the	O
ability	O
to	O
reverse	O
MDR	O
was	O
tested	O
with	O
the	O
chemotherapeutic	O
agents	I:C0729502
SN	O
-	I:C0142710
38	I:C0142710
and	O
mitoxantrone	O
(	O
mitoxantrone	B:C0026259
)	O
.	O

Interaction	O
of	O
the	O
compounds	B:C1706082
with	O
ABCG2	O
was	O
investigated	O
by	O
a	O
colorimetric	O
ATPase	O
assay	O
.	O

Interaction	O
of	O
the	O
compounds	O
with	O
ABCG2	B:C0761993
was	O
investigated	O
by	O
a	O
colorimetric	O
ATPase	O
assay	O
.	O

Interaction	O
of	O
the	O
compounds	O
with	O
ABCG2	O
was	O
investigated	O
by	O
a	O
colorimetric	B:C1531834
ATPase	O
assay	O
.	O

Interaction	O
of	O
the	O
compounds	O
with	O
ABCG2	O
was	O
investigated	O
by	O
a	O
colorimetric	O
ATPase	B:C0001473
assay	O
.	O

Interaction	O
of	O
the	O
compounds	O
with	O
ABCG2	O
was	O
investigated	O
by	O
a	O
colorimetric	O
ATPase	O
assay	B:C2717977
.	O

Enzyme	O
kinetic	O
studies	O
were	O
carried	O
out	O
with	O
Hoechst	B:C0062907
33342	I:C0062907
as	O
fluorescent	O
dye	I:C0016320
and	O
substrate	O
of	O
ABCG2	O
to	O
elucidate	O
the	O
compounds	O
binding	O
modes	O
.	O

Enzyme	O
kinetic	O
studies	O
were	O
carried	O
out	O
with	O
Hoechst	O
33342	I:C0062907
as	O
fluorescent	B:C0016320
dye	I:C0016320
and	O
substrate	O
of	O
ABCG2	O
to	O
elucidate	O
the	O
compounds	O
binding	O
modes	O
.	O

Enzyme	O
kinetic	O
studies	O
were	O
carried	O
out	O
with	O
Hoechst	O
33342	I:C0062907
as	O
fluorescent	O
dye	I:C0016320
and	O
substrate	O
of	O
ABCG2	B:C0761993
to	O
elucidate	O
the	O
compounds	O
binding	O
modes	O
.	O

Enzyme	O
kinetic	O
studies	O
were	O
carried	O
out	O
with	O
Hoechst	O
33342	I:C0062907
as	O
fluorescent	O
dye	I:C0016320
and	O
substrate	O
of	O
ABCG2	O
to	O
elucidate	O
the	O
compounds	B:C1706082
binding	O
modes	O
.	O

